The first in ASTCT's new CAR T Webinar Series aired on June 9, 2021 with our speaker, Dr. Marcela Maus, and our moderator, Dr. Armin Ghobadi. This webinar, 'CAR T Basics and Biology' covered an overall review of CAR T Biology, the general process of generating CAR T, CAR T targets, the future directions of CAR T biology, and more!

Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.

The second in ASTCT's CAR-T Webinar Series aired on June 29, 2021 at 2 PM CT with speaker, Dr. Frederick Locke, and our moderator, Dr. Akshay Sharma. This webinar, 'Clinical Advances in CAR T-Cell Therapy' covered a review of approved CAR-T products, practical aspects of referrals, eligibility, leukapheresis, and more! If you have any questions you would like to submit for the Q&A with Dr. Locke, please email info@astct.org.

Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.

This webinar aired on July 28, 2021 at 1 PM CT for the third installment of the CAR T Webinar Series from ASTCT. This webinar featured a presentation by Dr. Scott Goldsmith, highlighting the key areas of CAR T vs. Transplant, including consultation, day to day management, sequential therapy, and the pros and cons of each. The webinar also included a robust panel discussion on these topics moderated by Dr. Tania Jain, and featuring Dr. Samantha Jaglowski, Dr. John DiPersio, Dr. Brian Hill, and Dr. Mazyar Shadman.

Speaker and Moderator Bios:

- Dr. Tania Jain is an Assistant professor of oncology at Johns Hopkins and also leads the adult CAR T program at Hopkins. She currently serves as Vice Chair to the ASTCT Committee on Education, and is an active member of other ASTCT Committees and Special Interest Groups.
- Dr. Scott Goldsmith is a newly graduated heme onc fellow from Washington University, St Louis and is on his way to City of Hope, Los Angeles (via Florida btw) to start his new faculty position as assistant professor in a week.
- Dr. Mazyar Shadman is an associate professor at University of Washington (UW) and Fred Hutchinson Cancer Research Center. He is a hematologic malignancies expert who specializes in treating patients with lymphoma/ chronic lymphocytic leukemia (CLL). He is involved in clinical trials using novel therapeutic agents, immunotherapy (CAR-T cell), and stem cell transplant for treatment of lymphoid malignancies with a focus on CLL.  
- Dr. Brian Hill is the Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute. His clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma.  He is the principal investigator of multiple on-going clinical trials of developmental therapeutics including novel cellular therapies.  
- Dr. John F. DiPersio, Deputy Director, Alvin J. Siteman Cancer Center, Director, Center for Gene and Cellular Immunotherapy and Chief of the Division of Oncology at Washington University School of Medicine in St. Louis. Dr. DiPersio’s research focuses on fundamental and translational aspects of leukemia and stem cell biology.
- Dr. Samantha Jaglowski is an associate professor of hematology and the medical director of the Blood and Marrow Transplant Program at The Ohio State University, specializing in stem cell transplants for patients battling lymphoma and CLL. Her current research includes a phase II study of CTL-019, a CD19-specific CAR-T therapy for the treatment of diffuse large B-cell lymphoma (DLBCL)

Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.

This webinar aired on August 30, at 2 PM CT and is the fourth installment of the CAR T Webinar Series from ASTCT. This webinar featured a presentation by Dr. Martina Pennisi, highlighting the key areas of CAR T toxicity management, including CRS/ICANS grading and management, as well as late post-infusion care. There was also a robust panel discussion on these topics moderated by Dr. Mariana Lucena, and featuring Dr. Shannon Maude, Dr. Sattva Neelapu, Dr. Yi Lin.

Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.

This webinar aired live on October 28, 2021, as the fifth installment of the CAR T Webinar Series from ASTCT. This webinar featured presentations from Dr. Renato Cunha, Dr. Katie Gatwood, and Dr. Zahra Mahmoudjafari highlighting the key areas of logistics for operating CAR T programs, including reimbursement structure, inpatient vs. outpatient settings, programs in developing countries, data management, and clinical trials. There was also a robust panel discussion on these topics moderated by Dr. Antonio Macedo.

Speakers:

Dr. Katie Gatwood is a board-certified oncology pharmacist practicing as a Clinical Pharmacist Specialist in Adult Stem Cell Transplant and Cellular Therapy at Vanderbilt University Medical Center in Nashville, TN. She is passionate about clinical research and education, and has authored several publications and textbook chapters related to management of cellular therapy patients, including chimeric antigen receptor T-cell therapy. She is an active member of the American Society for Transplantation and Cellular Therapy (ASTCT) and was the recipient of the 2021 ASTCT Pharmacy SIG New Practitioner Award.

Dr. Zahra Mahmoudjafari is a board certified oncology pharmacist. She earned her doctorate of pharmacy at the University of Missouri-Kansas City and completed her pharmacy practice residency at The Ohio State University Medical Center in Columbus, Ohio and her oncology specialty residency the Huntsman Cancer Institute in Salt Lake City, Utah. She currently works as a Clinical Pharmacy Manager for Hematology/Blood and Marrow Transplant and Cellular Therapeutics at the University of Kansas Health System. She also currently serves as the residency program director for the PGY2 Oncology residency program. She maintains active organizational involvement with the Hematology Oncology Pharmacists Association (HOPA), Advanced Topics for Oncology Pharmacy Professionals (ATOPP) as well as the American Society for Transplantation and Cellular Therapeutics (ASTCT) where she had served as chair of the Pharmacy Special Interest Group and participates in committees such as the Practice Guidelines Committee, Government Relations Committee and Content Committee.

Dr. Renato Cunha graduated in Medicine from the Faculty of Medicine of the Federal University of Uberlândia, and was a Clinical Fellow in Hematology (2009), and Bone Marrow Transplantation and Cell Therapy (2010) at the Clinical Hospital of Ribeirão Preto Medical School of University of São Paulo. Postdoctoral Fellowship in Bone Marrow Transplantation and Cell Therapy at the National Cancer Institute (ETIBNCI/NHI) in Bethesda, USA (2015-2018). Member of the Brazilian Society of Bone Marrow Transplant, the American College Physician, the American Society of Hematology, and the American Society for Transplantation and Cellular Therapy. Currently, Assistant Professor of Medicine and Head of the Bone Marrow Transplantation and Cell Therapy Unit at the Clinical Hospital of Ribeirão Preto Medical School of the University of São Paulo (BMTU-HCFMRPUSP). In 2018 was awarded the ASH Global Research Award and in 2019, performed the first car t-cell treatment in Latin America in Ribeirão Preto, Brazil. In 2021, coordinate the first Brazilian Consensus of Advanced Cellular Therapy of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy.

Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.

This webinar aired on January 20, 2022 at 1:30 PM CT, as the sixth and final installment of the ASTCT CAR T Webinar Series. This webinar featured presentations from Dr. Debora Barton, Dr. Michael Caligiuri, and Dr. Nirav Shah highlighting novel therapies and opportunities for the future directions of the field. The presentations were followed by a robust panel discussion led by Dr. Yan Leyfman and Dr. Armin Ghobadi.

Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.